tbuckley/cabot-search huggingface dataset:
Circular RNA circHERC4 as a novel oncogenic driver to promote tumor metastasis via the miR-556-5p/CTBP2/E-cadherin axis in colorectal cancer
Authors: Jiehua He, Ziqiang Chu, Wei Lai, Qiusheng Lan, Yujie Zeng, Daning Lu, Shaowen Jin, Heyang Xu, Pengwei Su, Dong Yin, Zhonghua Chu, Lu Liu
Journal: Journal of Hematology & Oncology (2021)

The main cause of death in colorectal cancer patients is metastasis. Accumulating evidences suggest that circRNA plays pivotal roles in cancer initiation and development. However, the underlying molecular mechanisms of circRNAs that orchestrate cancer metastasis remain vague and need further clarification. Two paired CRC and adjacent normal tissues were used to screen the upregulated circRNAs by circRNA-seq; then, cell invasion assay was applied to confirm the functional invasion-related circRNAs. According to the above methods, circHERC4 (hsa_circ_0007113) was selected for further research. Next, we investigated the clinical significance of circHERC4 in a large cohort of patients with CRC. The oncogenic activity of circHERC4 was investigated in both CRC cell lines and animal xenograft studies. Finally, we explored the molecular mechanisms underlying circHERC4 as a malignant driver. We demonstrated that circHERC4 was aberrantly elevated in CRC tissues (P < 0.001), and was positively associated with lymph node metastasis and advanced tumor grade (P < 0.01). Notably, the expression of circHERC4 was associated with worse survival in patients with CRC. Silencing of circHERC4 significantly inhibited the proliferation and migration of two highly aggressive CRC cell lines and reduced liver and lung metastasis in vivo. Mechanistically, we revealed that circHERC4 inactivated the tumor suppressor, miR-556-5p, leading to the activation of CTBP2/E-cadherin pathway which promotes tumor metastasis in CRC. CircHERC4 exerts critical roles in promoting tumor aggressiveness through miR-556-5p/CTBP2/E-cadherin pathway and is a prognostic biomarker of the disease, suggesting that circHERC4 may serve as an exploitable therapeutic target for patients with CRC.
Abstract 9546: Cancer Therapeutics-Related Cardiac Dysfunction is Associated With High Risk of Cancer-Related Mortality in Patients Treated With Anthracycline-Containing Chemotherapy
Authors: Masayoshi Oikawa, Daiki Yaegashi, Sayoko Yokokawa, Tetsuro Yokokawa, Tomofumi Misaka, Takamasa Sato, Takashi Kaneshiro, ATSUSHI KOBAYASHI, Akiomi Yoshihisa, Kazuhiko Nakazato, Takafumi Ishida, Yasuchika Takeishi
Journal: Circulation (2021)

Background: Cancer therapeutics-related cardiac dysfunction (CTRCD) is a concerning problem in anthracycline-containing chemotherapy. However, the impact of CTRCD on cancer-related mortality is remained to be elucidated. Methods: Consecutive 174 patients planned for anthracycline-containing chemotherapy were enrolled. Echocardiography and blood test were performed at baseline, 3 months, 6 months, 12 months after starting chemotherapy, and after that every 3 months until cardiotoxic chemotherapy was completed. Results: Of 174 patients, CTRCD was developed in 16 patients (CTRCD group, median onset was 8 months), and the other patients (no-CTRCD group) showed normal left ventricular ejection fraction (LVEF). CTRCD group showed higher levels of peak troponin I (0.05 [0.04-0.16] ng/ml vs. 0.02 [0.02-0.04] ng/ml, P&lt;0.001), peak B-type natriuretic peptide (59 [26-161] pg/ml vs. 25 [15-41] pg/ml, P=0.001), and lower LVEF at 12-month (54.1±7.5% vs. 64.6±4.8%, P&lt;0.001) compared to no-CTRCD group. When we set the cut-off value of troponin I at 0.03 ng/ml, sensitivity, specificity, and area under the curve to predict CTRCD were 88%, 72%, and 0.792, respectively. In CTRCD group, 4 patients (25%) discontinued cardiotoxic chemotherapy due to CTRCD, and 12 patients (75%) showed recovered LVEF to more than 53%. In total study subjects, no patients presented cardiac death in follow up period (median 1056 days), but 22 patients (13%) died due to cancer progression. Kaplan-Meier analysis revealed that CTRCD group showed higher cancer-related mortality compared to no-CTRCD group (figure, P&lt;0.001). Multivariate Cox-proportional hazard analysis showed that CTRCD was an independent risk factor for cancer death (HR 4.639, 95%CI [1.691-12.730], P=0.003). Conclusion: The development of CTRCD was associated with high risk of cancer death, but not with cardiac death. Cardioprotective treatment and careful cancer monitoring are required to the patients with CTRCD.
<i>In Situ</i> Vaccination Induces Changes in Follicular Lymphoma Tumor Cells That Correlate with Abscopal Clinical Regressions
Authors: Sarah Haebe, Tanaya Shree, Grady Day, Anuja Sathe, Debra K. Czerwinski, Susan M. Grimes, Steven R. Long, Brock Martin, Richard Hoppe, Hanlee P. Ji, Ronald Levy
Journal: Blood (2021)
Safety and Efficacy of Early-Start Deferiprone in Infants and Young Children with Beta-Thalassemia (START study)
Authors: Mohsen Saleh Elalfy, Amal El-Beshlawy, Amira Adly, Fatma Soliman Elsayed Ebeid, Caroline Fradette, David Lee, Noemi T Temin, Fernando Tricta, Anna Rozova, Mona Hamdy
Journal: Blood (2021)
Discovering metabolite quantitative trait loci in asthma using an isolated population
Authors: Randi K. Johnson, Tonya Brunetti, Kevin Quinn, Katrina Doenges, Monica Campbell, Christopher Arehart, Margaret A. Taub, Rasika A. Mathias, Nichole Reisdorph, Kathleen C. Barnes, Michelle Daya
Journal: Journal of Allergy and Clinical Immunology (2021)
OM301, a Synthetic Polypeptide Containing the p53TA (Transactivation) Domain, Impairs Mitochondrial Activity and Survival of Myeloma Cells
Authors: Lokesh Nigam, Yinghui Zhu, Estelle Troadec, Enrico Caserta, Ada Dona', James F Sanchez, Amrita Y. Krishnan, Le Xuan Truong Nguyen, Guido Marcucci, Flavia Pichiorri
Journal: Blood (2021)
Abstract 8922: Provider Preferences Drive AF Ablation Cost Variability
Authors: Brian Zenger, Haojia Li, T. J Bunch, Candice Crawford, James C Fang, Rachel Hess, Chase Maires, Ravi Ranjan, Yue Zhang, Benjamin A Steinberg
Journal: Circulation (2021)

Background: AF ablation approaches and outcomes vary. Very little work has been done to assess the variability of ablation costs to health systems and drivers of variability. Objective: Determine the drivers of cost variability in AF ablation procedures. Methods: We assessed the costs of AF ablation procedures performed between 2013-2020 at a single tertiary care center. Cost to the health system were inflation-adjusted and separated into facility, imaging, implant, pharmacy, supply, labs, and other services. Only patients who were outpatient and had an ablation by an operator who performed &gt;10 procedures were included. Lasso multivariable regression was used to identify the primary drivers of variability in costs, including operator and patient characteristics. Results: 1072 patients with 1284 AF ablations were included (age: 65.1, SD: 11.0; men: 68%; CHADS2-Vasc: 2.8, SD: 1.9, beta blockers: 63%, non-white race: 6%). Procedures were performed by 8 operators. Proportional contributions to overall costs are shown in the Figure. Regression analysis demonstrated higher average cost for men, (1.25%), non-white race (2.6%), beta-blocker use (1.9%), prior ablation (0.98%), anticoagulation use (1.4%), and operator (highest operator cost increase vs. lowest, 18%). There was no relation to CHADS2-Vasc or age. Cost variability was primarily driven by supplies including catheters and other equipment. Conclusion: Cost variability was only modestly related to patient characteristics. The largest contributor to cost in AF ablations was supplies, which are primarily operator dependent.
Abstract 13866: Quantity of Cardiovascular Risk Factors and Associated Outcomes in Young Women With ST-Elevation Myocardial Infarction
Authors: Mehmet Yildiz, Rebekah H Lantz, Georgia M Mattingly, Christian W Schmidt, Scott W Sharkey, Heather S Rohm, Jenny Chambers, Teresa Coulson, Timothy D Henry, Odayme Quesada
Journal: Circulation (2021)

Introduction: Despite the remarkable progress in STEMI care, the mortality rates in young women with STEMI remain high. It remains unclear whether this is related to the number of cardiovascular (CV) risk factors. Methods: From 2010 to 2020, we evaluated 10,441 consecutive STEMI patients, including 3,150 (30%) women enrolled in prospective Midwest STEMI Consortium registry, constituted of Minneapolis Heart Institute, Minneapolis, MN, The Christ Hospital, Cincinnati, OH, Prairie Heart Institute, Springfield, IL, and Iowa Heart Center, Des Moines, IA. We categorized baseline CV risk factors (hypertension, dyslipidemia, diabetes, smoking, and family history of CAD) in the 477 (15%) women &lt;55 years and without previous history of CAD. Results: Smoking was the most common, and diabetes the least common CV risk factor. Of the 477 women, 161 (33.8%) had 0 or 1 CV risk factor, 132 (27.7%) had 2, and 184 (38.6%) had at least 3 CV risk factors. As the number of CV risk factors decreased, non-atherosclerotic STEMI etiologies -SCAD or Takotsubo syndrome- increased, as did the incidences of cardiogenic shock or cardiac arrest. There were no differences in reperfusion strategies or time among patients with 0 or more CV risk factors; however, as the number of CV risk factors decreased, patients were less likely to receive antiplatelet or statin at discharge. There was a trend toward higher death in the hospital with decreasing number of CV risk factors, but it did not reach statistical significance (p=0.075) (Table). Conclusions: Young women with fewer traditional CV risk factors more often presented with non-atherosclerotic causes of STEMI and higher incidences of cardiogenic shock or cardiac arrest and had a trend toward a higher risk of in-hospital death. Thus, future epidemiological studies are needed to determine if sex-specific risk enhancers, in addition to traditional CV risk factors, have a role in risk stratification among young women for future CV events.
Longitudinal Analysis of Gut Bacteriome, Mycobiome, Virome and Metabolome in Allogeneic Stem Cell Transplantation Reveals Susceptibility for Acute Graft-Versus-Host Disease
Authors: Erik Thiele Orberg, Elisabeth Meedt, Andreas Hiergeist, Jinling Xue, Sakhila Ghimire, Melanie Tiefgraber, Tina Eismann, Sophia Göldel, Peter Herhaus, Mareike Verbeek, Florian Bassermann, Michael Quante, Daniela Weber, Matthias Edinger, Daniel Wolff, Wolfgang Herr, Li Deng, André Gessner, Ernst Holler, Hendrik Poeck
Journal: Blood (2021)
Combination Therapy of Bcl-2/X L dual Inhibitor AZD0466 with Acalabrutinib to Overcome Therapeutic Resistance in Aggressive R/R Mantle Cell Lymphoma
Authors: Yijing Li, Yang Liu, Yuxuan Che, Joseph McIntosh, Alexa A Jordan, Angela Leeming, Courtney L Andersen, Justin Cidado, Jingling Jin, Vivian Changying Jiang, Michael Wang
Journal: Blood (2021)
Abstract 9161: Referral Patterns Do Not Contribute to Racial Differences in Catheter Ablation for Atrial Fibrillation
Authors: Jessica E Marot, Lindsay R Pool, Yoshihiro Tanaka, Celeste Witting, Sadiya S Khan, Rod S Passman
Journal: Circulation (2021)

Introduction: Non-Hispanic Black (NHB) adults with atrial fibrillation (AF) are less likely to undergo catheter ablation (AFCA) compared with non-Hispanic White (NHW) adults even among those with heart failure and even though previous studies have shown that NHB patients with AF were more symptomatic. Hypothesis: We hypothesize that differences in outpatient referrals to Cardiology and Electrophysiology (EP) contribute to the racial disparity in AFCA. Methods: Using data from the Northwestern Medicine Enterprise Data Warehouse, we curated a retrospective cohort of NHB and NHW patients with newly diagnosed AF between 1/1/2011 and 12/31/2019 in an outpatient office visit to Internal Medicine/Primary Care (IM/PC), Cardiology, or Heart Failure (HF). Rates of AFCA and referral rates from IM/PC to Cardiology or EP and from Cardiology and HF to EP were compared between NHB and NHW patients using logistic regression models adjusted for demographic characteristics and comorbidities. Results: Of the 5,555 included patients, the mean age was 68 years (SD 13.4), 61% were male, 15% were NHB, and the mean CHA 2 DS 2- VASc score was 3.5 (SD 2.0). 373 patients (6.7%) underwent AFCA. NHB patients had a higher prevalence of comorbidities. NHB patients were significantly less likely to undergo AFCA compared with NHW patients (OR 0.61, 95% CI 0.40-0.92, p = 0.02), and this difference persisted even when limited to the subset of patients who had visited EP (N=1,840, OR 0.65, CI 0.42-0.98, p = 0.04). Among patients diagnosed in IM/PC, NHB patients were 1.47 times more likely to be referred to Cardiology than NHW patients (CI 1.09-1.97, p = 0.01), but the rates of referral to EP were similar (OR 0.94, CI 0.72-1.24, p = 0.68) ( Figure ). Conclusion: NHB patients diagnosed in the outpatient setting are less likely to undergo AFCA compared with NHW patients, but referral patterns do not explain these findings. Exploration of other factors should be considered to mitigate disparities in care related to AFCA.
Incidence and Outcomes of Post-Transplant Lymphoproliferative Disease after 5365 Solid Organ Transplants over a 20 Year Period at 2 UK Transplant Centres
Authors: Anna Santarsieri, Andrew Butler, William Gelson, Stephen Pettit, John F Rudge, Nicholas Torpey, Benjamin J Uttenthal, Charles Crawley, George A Follows
Journal: Blood (2021)
Discordance between Treatment Guideline Recommendations and Real-World Practice in a Group of Large Integrated Delivery Networks for Venous Thromboembolism (VTE) Patients: A Closer Look at VTE Patients with Cancer
Authors: Juzer Lotya, Amol Dhamane, Lisa Rosenblatt, Jenny Jiang, Deysia Levin, Eric Gemmen, Sara Waugh, Jennifer D Guo, Rasha Khatib, Vinay Shah, Michael Dorsch, Xuemei Luo
Journal: Blood (2021)
Comparison of and Immune Reconstitution and Graft Versus Host Disease in 30mg/Kg Anti-T-Lymphocyte Globuline with 60mg/Kg ATLG As Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Myeloablative Peripheral Blood Stem Cell Transplantation
Authors: Radwan Massoud, Evgeny Klyuchnikov, Nico Gagelmann, Tatjana Zabelina, Wolschke Christine, Francis Ayuketang Ayuk, Ulrike Fritsche-Friedland, Axel R. Zander, Nicolaus Kröger
Journal: Blood (2021)
<i>Pediatric Single Cell Cancer Atlas: An Integrative Web-Based Resource for Single Cell Transcriptome Data from Pediatric Leukemias</i>
Authors: Hope L Mumme, Swati S Bhasin, Beena E Thomas, Bhakti Dwivedi, Deborah DeRyckere, Sharon M. Castellino, Daniel S. Wechsler, Sunil S. Raikar, Christopher C. Porter, Douglas K Graham, Manoj Bhasin
Journal: Blood (2021)
Abstract 9807: Sirt1 Ameliorates High Fat Diet-Induced Diastolic Heart Failure
Authors: Shinichi Oka, Peiyong Zhai, Junichi Sadoshima
Journal: Circulation (2021)

Approximately half of heart failure patients are diagnosed with diastolic heart failure. Sirt1 is a protein deacetylase that inhibits cardiac fibrosis and diastolic dysfunction. We investigated how Sirt1 inhibits cardiac fibrosis and diastolic dysfunction using a high fat diet (HFD)-induced obesity model with cardiac-specific Sirt1 knockout (Sirt1cKO) and overexpression (Sirt1cTG) mice. In addition to diastolic dysfunction, HFD (3 months)-induced cardiac fibrosis was promoted in Sirt1cKO (Relative fibrosis: wild-type mice (WT) Normal Diet (ND): 1.0; WT HFD: 2.4; Sirt1cKO ND: 1.2; Sirt1cKO HFD: 6.2*, p&lt;0.05 vs WT HFD) but inhibited in Sirt1cTG mice. Cardiomyocyte-specific gene expression analysis with Ribo-tag mice revealed that TGFβ1 mRNA is increased in Sirt1cKO mice during HFD consumption (relative TGFβ1 mRNA: WT ND: 1.0; WT HFD: 1.3; Sirt1cKO ND: 1.1; Sirt1cKO HFD: 1.9*, p&lt;0.05 vs WT HFD). A TGFβ1 receptor inhibitor inhibited HFD-induced cardiac fibrosis and diastolic dysfunction in Sirt1cKO mice, suggesting that loss of Sirt1 promotes cardiac fibrosis and diastolic dysfunction partly though TGFβ1. ChIP-sequencing revealed that Sirt1 localized to the TGFβ1 promoter, overlapping with Smad binding elements. Co-immunoprecipitation assays showed that Sirt1 bound to Smad3 in the heart. Reporter gene assays showed that Sirt1 inhibited the TGFβ1 promoter activity through Smad3 (Relative activity: control 1.0; Sirt1 overexpression: 0.35; Sirt1 overexpression with Smad3 knockdown: 0.89*, p&lt;0.05 vs Sirt1). DNA binding assays with the TGFβ1 promoter region showed that Sirt1 binds to the TGFβ1 promoter, which was inhibited by Smad3 knockdown (relative binding to TGFβ1 promoter: Control: 1.0; Smad3 knockdown: 0.45*, p&lt;0.05 vs Control). Taken together, the data show that Sirt1 binds to the TGFβ1 promoter through Smad3, thereby suppressing TGFβ1 expression and subsequent cardiac fibrosis and diastolic dysfunction.
Long-Term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
Authors: Kevin H.M. Kuo, D. Mark Layton, Ashutosh Lal, Hanny Al-Samkari, Joy Bhatia, Penelope A. Kosinski, Bo Tong, Megan Lynch, Katrin Uhlig, Elliott Vichinsky
Journal: Blood (2021)
High-Dose Carfilzomib Recaptures Response in Relapsed/Refractory Multiple Myeloma Resistant to Low-Dose Carfilzomib By Co-Inhibiting β2 Subunit of Proteasome Complex: The First in Human Evidence
Authors: Xiang Zhou, Andrej Besse, Jessica Peter, Max Mendez Lopez, Larissa Haertle, Umair Munawar, Seungbin Han, Elmer Maurits, Herman S. Overkleeft, Hermann Einsele, Christoph Driessen, Martin Kortuem, Lenka Besse, Leo Rasche
Journal: Blood (2021)
Abstract 9298: Associations of Demographic, Socioeconomic, and Cognitive Characteristics With Mobile Health Access Indicate a Digital Divide: Results from the Multi-Ethnic Study of Atherosclerosis (MESA)
Authors: Reshmi J Patel, Jie Ding, Francoise A Marvel, Rongzi Shan, Tim B Plante, Michael J Blaha, Wendy Post, Seth S Martin
Journal: Circulation (2021)

Background: Mobile health (mHealth) has an emerging role in prevention of cardiovascular disease (CVD), but there is rising concern about inequities in access. This study aimed to evaluate possible divides in mHealth access by demographic, socioeconomic, and cognitive characteristics. Methods: The Multi-Ethnic Study of Atherosclerosis (MESA) is a population-based observational cohort study of adults free of CVD at baseline in 2000-02. Multivariable logistic regression modeling assessed associations of age, sex, race/ethnicity, education level, annual family income, health insurance status, and Cognitive Abilities Screening Instrument (CASI) with three mHealth outcomes in 2019-20. Results: Among 2796 participants (mean [SD] age 75 [9], 55% women, 40% White, 25% Black, 21% Hispanic, 14% Chinese), 63% (n=1756) had internet access (IA), 65% (n=1828) owned a computing device (CD), and 9% (n=248) owned a fitness tracker (FT). There were lower odds of all mHealth outcomes for older age (per 10 years odds ratios (OR) from 0.35 to 0.55), Hispanic ethnicity (vs. White 0.49-0.59), and lower income (&lt;$35,000 vs. ≥$75,000 0.32-0.47) (Figure). For IA and CD, lower odds were seen with Black race (vs. White OR [95% CI] 0.54 [0.41-0.73], 0.66 [0.41-0.73]) and higher odds with higher education (≥Bachelor’s degree vs. &lt;high school 4.75 [3.19-7.12], 3.08 [2.09-4.56]), HMO/private health insurance (vs. other 1.66 [1.31-2.11], 3.08 [2.09-4.56]), and higher CASI score (per 10 points 1.14 [1.02-1.27], 1.15 [1.04-1.28]). There was an inconsistent pattern for Chinese race and sex. Chinese race (vs. White) had lower odds of IA and FT but higher odds of CD, and men (vs. women) had higher odds of CD but lower odds of FT. All results were from a multivariable model. Discussion: All mHealth outcomes varied by major demographic, socioeconomic, and cognitive characteristics, indicating the presence of a digital divide. mHealth interventions should consider individual barriers to access.
Studies on Tissue Metabolism by Means of in Vivo Metabolic Blocking Technics
Authors: Harris Busch, Van R. Potter
Journal: Cancer Research (1953)

1.  The distribution of radioactivity in the various peaks of the acid profiles of the tumor and other tissues of rats bearing Flexner-Jobling tumors has been studied and 60–100 per cent of the total radioactivity can be accounted for either as radioactivity in volatile compounds or in the elements of the acid profile.

2.  The time course of incorporation of radioactivity from acetate-1-C14 into succinate pools induced by malonate in tumors and normal tissues reveals maximal incorporation in normal tissues 2–4 minutes after the intraperitoneal injection of the precursor.

3.  The total radioactivity in the succinate pool accounts for 30 per cent of the total radioactivity within the kidney and about 10 per cent in other tissues. Very high percentages of the total radioactivity are found in peaks 2 and 3 of the acid profiles, in a number of tissues.

4.  The bulk of the count in the Flexner-Jobling tumor remains volatile for 30 minutes after the injection of the precursor. This finding and the very low incorporation of radioactivity in the pool of succinate within the tumor differentiate this tissue from normal heart, lung, spleen, liver, and skeletal muscle.
Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL
Authors: Thomas Chatzikonstantinou, Lydia Scarfo, Christos Demosthenous, Jana Kotaskova, Gloria Iacoboni, Evangelia Minga, Dimitra Chammou, Georgios Karakatsoulis, Elisa Albi, Miguel Alcoceba, Shaimaa El-Ashwah, Francesca Bacchiarri, Mehreen Ali Khan, Thérèse Aurran, Anne Calleja, Ramona Cassin, Sofia Chatzileontiadou, Amy Christian, Rainer Claus, Rosa Collado, Marcos Daniel De Deus Santos, Zadie Davis, Maria Dimou, David Donaldson, Gimena Dos Santos, Barbara Dreta, Maria Efstathopoulou, Alicia Enrico, Alberto Fresa, Sara Galimberti, Rocío García-Serra, Isabel González-Gascón Y Marín, Alessandro Gozzetti, Valerio Guarente, Sean Harrop, Eleftheria Hatzimichael, Yair Herishanu, Luca Inchiappa, Michalis Iskas, Ozren Jaksic, Susanne R. Janssen, Elzbieta Kalicinska, Volkan Karakus, Arnon P. Kater, Bonnie Kho, Iliana Konstantinou, Thomas Longval, Maya Koren-Michowitz, Ioannis Kotsianidis, Robert J. Kreitman, Uttam Kumar Nath, Jorge Labrador, Deepesh Lad, Kamel Laribi, Ilana Levy, Alberto Lopez-Garcia, Juan Marquet Palomanes, Stanislava Maslejova, Carlota Mayor-Bastida, Fatiha Merabet, Biljana Mihaljevic, Ivana Milosevic, Fatima Miras, Riccardo Moia, Marta Morawska, Almudena Navarro-Bailón, David Oscier, Jacopo Olivieri, Tomáš Papajík, Maria Papaioannou, Cheyenne Pierie, Anna Puiggros, Gianluigi Reda, Gian Matteo Rigolin, Rosa Ruchlemer, Luana Schiattone, Omur Gokmen Sevindik, Yandong Shen, Martin Šimkovič, Svetlana Smirnova, Dina Sameh Soliman, Martin Špaček, Annett Schiwitza, Tamar Tadmor, Liat Tourjeman, Eric Tse, Andrea Visentin, Kristina Tomic, Michel Van Gelder, Theodoros P. Vassilakopoulos, Candida Vitale, George Vrachiolias, Vojin Vukovic, Zhenshu Xu, Lucrecia Yáñez, Munci Yagci, Mohamed A Yassin, Jana Zuchnicka, Maria K. Angelopoulou, Darko Antic, Bella V. Biderman, Mark Catherwood, Marta Coscia, Antonio Cuneo, Fatih Demirkan, Blanca Espinet, Gianluca Gaidano, Romain Guièze, Olga Kalashnikova, Luca Laurenti, Stephen Mulligan, Roberta Murru, Eugene A. Nikitin, Panayiotis Panayiotidis, Gerasimos Pangalis, Irina Panovska, Viola Maria Popov, Šárka Pospíšilová, Lukas Smolej, Paolo Sportoletti, Niki Stavroyianni, Constantine S. Tam, Livio Trentin, Marek Trněný, Francesc Bosch Albareda, Michael Doubek, Anastasia Chatzidimitriou, Paolo Ghia, Kostas Stamatopoulos
Journal: Blood (2021)